Discover 1,965 paid clinical trials in Miramar, Florida. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 1,965
Active & Responsive
A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes
Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
for
Atopic Dermatitis (AD)
Location: Miramar FL, Miami FL, Fort Lauderdale FL, Wilmington NC,
Sponsor: Enveda Therapeutics
Sex: All
Age: 18 - 70+
Code: NCT07298395
Phase2, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
Active & Responsive
A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity
for
Obesity, Overweight and/or Obesity, Overweight
Location: Miramar FL, Pembroke Pines FL, New Port Richey FL,
Sponsor: Pfizer
Sex: All
Age: 18+
Code: NCT07595549
Phase3, Recruiting
Active & Responsive
A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes
for
Diabetes Mellitus, Type 2
Location: Miramar FL, Hollywood FL, Weston FL,
Sponsor: Novo Nordisk A/S
Sex: All
Age: 18 - 70+
Code: NCT07668388
Phase2, Recruiting
Active & Responsive
AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight
for
Obesity
Location: Miramar FL, Orlando FL, Charleston SC,
Sponsor: Novo Nordisk A/S
Sex: All
Age: 18+
Code: NCT07339423
Phase3, Recruiting
Active & Responsive
A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity
for
Obesity
Location: Miramar FL, Hollywood FL, Ocoee FL, Montgomery AL,
Sponsor: Novo Nordisk A/S
Sex: All
Age: 18+
Code: NCT07639021
Phase2, Recruiting
Active & Responsive
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity